News

Stryker has announced that it has finalized its acquisition of Amplitude Vascular Systems (AVS) for an undisclosed sum.

AVS specializes in an intravascular lithotripsy (IVL) platform aimed at treating calcified peripheral arterial disease (PAD). The technology utilizes pulsed CO₂-generated pressure waves delivered evenly through an IVL balloon catheter.This approach breaks down calcium deposits, improves luminal gain, and enhances catheter delivery, treatment speed, and overall therapy efficiency.

Based in Waltham, Massachusetts, AVS secured FDA investigational device exemption approval for its Pulse system in 2024. The company later reported promising clinical findings for the IVL platform last fall.

With this latest strategic acquisition, Portage, Michigan–based Stryker enters the rapidly growing IVL market, currently dominated by Johnson & Johnson’s Shockwave Medical. Other firms, including FastWave Medical, Elixir Medical, and Vantis Vascular, are also developing IVL technologies, while Boston Scientific joined the sector through its acquisition of Bolt Medical last year. Abbott is likewise developing its own platform.

Stryker believes the acquisition will further strengthen its Peripheral Vascular (PV) portfolio by adding advanced revascularization capabilities. The deal follows another recent expansion of the portfolio through the 2025 acquisition of Inari Medical.

“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”

© Stryker Corporation